Annex Advisory Services LLC Purchases Shares of 6,113 Pfizer Inc. (NYSE:PFE)

Annex Advisory Services LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,113 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

Other large investors also recently bought and sold shares of the company. Corbett Road Capital Management LLC purchased a new position in shares of Pfizer during the second quarter worth about $25,000. Reitz Capital Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Rocky Mountain Advisers LLC grew its position in shares of Pfizer by 847.5% during the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,000 shares during the last quarter. JJJ Advisors Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at about $44,000. Finally, NuWave Investment Management LLC grew its position in shares of Pfizer by 439.7% during the 3rd quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,196 shares during the last quarter. 69.08% of the stock is owned by institutional investors and hedge funds.

In related news, Director Ronald E. Blaylock purchased 13,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the acquisition, the director now owns 4,000 shares of the company’s stock, valued at approximately $154,200. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.08% of the company’s stock.

A number of equities research analysts recently weighed in on PFE shares. Berenberg Bank started coverage on shares of Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price objective for the company. SVB Leerink upped their price target on shares of Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research note on Wednesday, July 29th. Atlantic Securities lowered shares of Pfizer from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $44.00 to $39.00 in a research note on Monday, October 12th. Morgan Stanley upped their price target on shares of Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Finally, Mizuho reaffirmed a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $39.81.

Shares of NYSE:PFE traded down $0.30 during trading on Monday, hitting $37.88. 1,066,972 shares of the company’s stock were exchanged, compared to its average volume of 28,235,811. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $40.97. The business’s 50-day simple moving average is $36.59 and its 200 day simple moving average is $36.49. The company has a market cap of $212.16 billion, a price-to-earnings ratio of 14.96, a PEG ratio of 3.10 and a beta of 0.66.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.80 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.84 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a $0.38 dividend. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s dividend payout ratio is presently 51.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: How to start trading in the forex market?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.